Patents by Inventor Joaquina Faour

Joaquina Faour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition and method for treating neurological disease
    Patent number: 11890261
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: February 6, 2024
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 11833121
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: December 5, 2023
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20210353558
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 22, 2020
    Publication date: November 18, 2021
    Applicant: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20210353559
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2021
    Publication date: November 18, 2021
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • Dose-dumping resistant controlled release dosage form
    Patent number: 10695336
    Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 30, 2020
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20200129454
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20200129455
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • Composition and method for treating neurological disease
    Patent number: 10512617
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 24, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelösségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10500170
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: December 10, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10500171
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: December 10, 2019
    Assignee: Osmotica Kereskedelmi és SzolgáltatóKorlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10500172
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 10, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247329
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247328
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 7, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247327
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 7, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247331
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 5, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247330
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • DOSE-DUMPING RESISTANT CONTROLLED RELEASE DOSAGE FORM
    Publication number: 20190167654
    Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
    Type: Application
    Filed: February 6, 2019
    Publication date: June 6, 2019
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: HERNAN D. BENEDETTI, CRISTIAN R. FRANCO, GUIDO S. BIGATTI, JOAQUINA FAOUR, ANA C. PASTINI
  • Dose-dumping resistant controlled release dosage form
    Patent number: 10265308
    Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: April 23, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
  • Composition and method for treating neurological disease
    Patent number: 10213393
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: February 26, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10213394
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: February 26, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo